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REVIEW CURRENTOPINION Effects of sodium glucose cotransporter 2 inhibitors
on mineral metabolism in type 2 diabetes mellitus1062-4821 Copyright  2019 The Aa b aJoanna Sophia J. Vinke , Hiddo J.L. Heerspink , and Martin H. de BorstPurpose of review
Sodium glucose cotransporter 2 (SGLT2) inhibitors are relatively novel antidiabetic drugs that improve
glycemic control and reduce cardiovascular outcomes as well as renal function decline. SGLT2 inhibitors
act by inhibiting glucose reabsorption in the proximal tubule of the kidney. Emerging data suggest that
these drugs may also influence bone and mineral metabolism. This review summarizes clinical trial data on
bone and mineral outcomes, and discusses potential underlying mechanisms.
Recent findings
Three large randomized controlled trials documented cardiovascular and renal protective effects of SGLT2
inhibitors. Recent studies indicate that SGLT2 inhibitors influence renal phosphate reabsorption and
calciuria. Although the CANVAS trial suggested an increased fracture risk associated with canagliflozin
compared with placebo, the vast majority of trials and meta-analyses did not demonstrate an increased
fracture risk associated with SGLT2 inhibitor use.
Summary
SGLT2 inhibitors have shown clinically relevant cardiovascular and renal protective effects. The long-term
implications for bone health, in particular in the context of chronic kidney disease, are still incompletely
understood and warrant further investigation.
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provided it is properly cited. The work cannot be changed in any way or
used commercially without permission from the journal.Diabetes mellitus is one of the most prevalent
chronic diseases worldwide, affecting an estimated
422million adult patients in 2014 [1]. Since 1980, its
prevalence has increased from 4.7 to 8.5% in adults
[1]. Diabetes was the cause of 1.5 million deaths in
2012 [1]. Type 2 diabetes mellitus (T2DM) is one of
the most common causes of chronic kidney disease,
and a major risk factor for cardiovascular disease.
Recently, promising new drugs have been intro-
duced for the treatment of T2DM, including sodium
glucose cotransporter 2 (SGLT2) inhibitors, dipepti-
dylpeptidase-4 (DPP4) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists. SGLT2 inhib-
itors have shown clinically relevant improvements
in cardiovascular outcomes and slower progression
of chronic kidney disease, especially in populations
with established cardiovascular disease. Recent data
from small trials suggest that SGLT2 inhibitors may
influence bone and mineral metabolism. Here, we
will first review the most important data from car-
dio-renal outcome studies with SLGT2 inhibitors.
Subsequently, wewill focus on their potential effects
on bone and mineral metabolism.uthor(s). Published by Wolters KluweINHIBITORS: MECHANISMS OF ACTION
Sodium-glucose cotransporters 1 (SGLT1) in intesti-
nal cells are essential for the absorption of dietary
glucose and galactose. SGLT2 cotransporters are
predominantly expressed in the proximal tubule
in the kidney, and reabsorb sodium and glucose
in collaboration with glucose transporters (Fig. 1)r Health, Inc. www.co-nephrolhypertens.com
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KEY POINTS
 SGLT2 inhibitors improve cardiovascular and renal
clinical outcomes.
 SGLT2 inhibitors might interfere with renal phosphate
reabsorption and induce calciuria.
 Some studies have suggested an increased fracture risk
associated with SGLT2 inhibitors, although the vast
majority of clinical trials and meta-analyses do not
show an increased fracture risk.
Mineral metabolism[2]. By blocking SGLT2 cotransporters, SGLT2 inhib-
itors induce glucosuria and therefore have a strong
glucose-lowering effect. Furthermore, osmotic
diuresis results in a decrease in blood pressure. Cur-
rently, three SGLT2 inhibitors are available: empa-
gliflozin and dapagliflozin selectively suppress the













FIGURE 1. Sodium-glucose cotransporter 2 (SGLT2) in the rena
the luminal side of the proximal renal tubule. On the basolateral s
glucose transporters (GLUT2). The intracellular sodium gradient, c
Naþ/Kþ ATPases. Potassium can passively cross the cell membra
2 www.co-nephrolhypertens.comSODIUM GLUCOSE COTRANSPORTER 2
INHIBITORS: CLINICAL OUTCOMES
In a number of trials, all SGLT2 inhibitors led to
statistically significant reductions in body weight,
varying between an average decline of 1.6 kg with
canagliflozin, and a decline of 2.4 kg with dapagli-





Furthermore, SGLT2 inhibitors reduced systolic
and diastolic blood pressure [5
&
,6,7]. In the CAN-
VAS trial, a large randomized controlled trial (RCT)
of 10 142 participants with T2DM, canagliflozin led
to a further glycosylated hemoglobin (HbA1C)
reduction by 0.58%, compared with placebo [7].
The beneficial effects of SGLT2 inhibitors on car-
diovascular outcomes in high-risk populations are
summarized in Fig. 2. The composite outcome of
major cardiovascular events (MACE: cardiovascular
mortality, nonfatal myocardial infarction or non-
fatal cerebro-vascular events) occurred significantly
less frequently with canagliflozin compared to pla-
cebo [HazardRatio (HR) 0.86; 95%confidence inter-





l tubule. SGLT2 reabsorbs sodium (Naþ) and glucose from
ide of the cell, glucose is exported into the circulation by
rucial for SGLT2 function, is maintained by the active
ne back into the circulation.
Volume 28  Number 00  Month 2019
CE: S.S.; MNH/280406; Total nos of Pages: 7;
MNH 280406
FIGURE 2. Effects of sodium glucose cotransporter 2 inhibitor on cardiovascular events in patients with type 2 diabetes
mellitus and increased cardiovascular risk. The EMPAREG trial and the CANVAS trial showed a significant reduction in
MACE (cardiovascular mortality, non-fatal myocardial infarction or non-fatal cerebro-vascular events) of empagliflozin and
canagliflozin, respectively. In the DECLARE trial however, the reduction in MACE was not significant with dapagliflozin. HR,
hazard ratio; 95% CI, 95%, 95% confidence interval.
Effects of sodium glucose cotransporter 2 inhibitors Vinke et al.patients with increased cardiovascular risk [7]. In
the EMPAREG OUTCOME trial, an RCT with 7020
patients with T2DM and preexisting cardiovascular
disease, empagliflozin provided similar results on
cardiovascular events (HR 0.86 compared with pla-
cebo; 95% CI 0.74–0.99, P¼0.04 for superiority)
[6]. In the DECLARE trial, an RCT comparing dapa-
fliglozin with placebo in 17160 diabetic patients
with atherosclerotic cardiovascular disease, the dif-
ference in MACE did not reach statistical signifi-
cance (HR 0.93; 95% CI 0.84–1.03; P¼0.17 for
superiority), although patients in the dapagliflozin
group had a 0.42% (95% CI; 0.40–0.45) greater
reduction in HbA1C compared to patients in the
placebo group [5
&
]. Long-term effects of SGLT2
inhibitors on HbA1C are more sustainable than
with DDP4 inhibitors and sulfonylurea derivates
[10].
SGLT2 inhibitors also have beneficial effects
on the kidney [11
&
]. Canagliflozin significantly
retarded the progression of albuminuria, and empa-
gliflozin slowed down renal function decline [7,12].SODIUM GLUCOSE COTRANSPORTER 2
INHIBITORS: ADVERSE EFFECTS
The adverse effects of SGLT2 inhibitors are generally
mild. Genital infections, such as balanitis and
vulvovaginitis, are the most common adverse





,10]. A higher incidence of diabetic1062-4821 Copyright  2019 The Author(s). Published by Wolters Kluweketoacidosis has been reported, especially in off-
label use of SGLT2 inhibitors in type 1 diabetic
patients, but also in T2DM [5
&
,10].
SGLT2 inhibitors do not increase the risk of
hypoglycemia [6,7,8
&
]. In the DECLARE trial, dapa-
gliflozin was even associated with a lower risk of
hypoglycemia than placebo (HR 0.68, CI 0.49–0.95,
P¼0.02) [5&]. Because of their mechanism of action,
SGLT2 inhibitors decrease circulating volume
and sodium. This may be beneficial for diabetic
patients with hypertension but may also lead to
hypotension.
Participants of the CANVAS study who received
canagliflozin had an increased incidence of volume
depletion as a result of osmotic diuresis and natri-
uresis (26 events per 1000 patient years with cana-
fliglozin versus 18.5 events with placebo, P¼0.009)
[7]. A meta-analysis of eight other RCTs showed a
trend toward an increased risk of complications
from volume depletion with canagliflozin com-
pared to placebo (HR 1.13, CI 0.74–1.73 with
100mg; HR 1.45, CI 0.98–2.13 with 300mg) [13].
In contrast, a number of individual studies compar-
ing SGLT2 inhibitors with placebo did not observe





thermore, in the CANVAS trial, a higher incidence of
amputations of the lower extremities has been
reported (HR 1.97, 95% CI 1.41–2.75) [7] In con-
trast, a similar signal was not observed in the
DECLARE trial: the amputation rate was similar to
placebo [5
&
].r Health, Inc. www.co-nephrolhypertens.com 3
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Mineral metabolismEFFECT OF DIABETES ON BONE AND
MINERAL METABOLISM
T2DM in itself is accompanied by an increased bone
mass density (BMD). This is most likely related to
anabolic effects of hyperinsulinism, lower bone
turnover and, generally, a higher BMI [3,14]. Para-
doxically, diabetic patients have a higher risk of
fractures compared to nondiabetic controls with
the same BMD score [15]. This discrepancy may
be partly explained by a higher fall risk, for example
due to diabetic neuropathy, but also several meta-
bolic processes and antidiabeticmedications impair-
ing bone quality are likely involved. In diabetes,
storage of advanced glycation end products such
as pentosidine in collagen stiffens the structure of
extracellular matrix, making it more brittle and
prone to fractures [3,14,16]. Furthermore, osteoblast
activity can be inhibited by hyperglycemia or thia-
zolidinediones [3,17,18]. Thiazolidinediones, which
also cause bone resorption, are well known to reduce
BMD and are associated with an increased fracture
risk [18–20]. Insulin may result in hypoglycemia,
increasing the risk of falls. In contrast, metformin
stimulates osteoblast activity and incretin-based
therapies (DPP4 inhibitors and GLP-1 analogues)
have an anabolic effect on bone formation [20,21].EFFECTS OF SODIUM GLUCOSE
COTRANSPORTER 2 INHIBITORS ON
CIRCULATING MARKERS OF MINERAL
METABOLISM
Classical physiological research performed in the
early 1980s, long before SGLT2 was cloned, already
suggested a mechanistic link between sodium-glu-
cose transport across the proximal tubular mem-
brane and mineral metabolism. In isolated renal
cortices of rabbits, the authors found that the trans-
porters of phosphate, glucose and alanine all made
use of the same sodium gradient, thereby limiting
each other [22]. Because SGLT2 inhibitors prevent
the cotransport and reabsorption of sodium and
glucose, the sodium gradient is preserved for the
sodium-dependent phosphate transport proteins IIa
(NaPi IIa, SLC24A1) and IIc (NaPi IIc, SLC34A3),
stimulating phosphate reabsorption at the proximal
tubule. These mechanistic studies were recently fur-
ther substantiated by two human studies with
SGLT2 inhibitors. In a single-blinded randomized
cross-over study with 25 healthy volunteers who
received either canagliflozin or a placebo during 5
days, canagliflozin was associated with glucosuria
[23
&&
]. During the first day, a transient but marked
increase in sodium excretion was observed in corre-
lation with a significant rise in serum phosphate.
These findings support the theory of phosphate4 www.co-nephrolhypertens.comretention induced by an enforced sodium gradient.
Calcium excretion increased slightly without caus-
ing any changes in serum calcium. A probable cause
of increased calcium excretion is the high tubular
flow as a result of osmotic diuresis, reducing para-
cellular calcium reabsorption in the proximal tubule
and reducing the calcium gradient between the
tubule and the medullar interstitium [24]. In chil-
dren with a genetic SGLT2 deficiency, familial renal
glucosuria, hypercalciuria is also a well-known phe-
nomenon [25].
Interestingly, serum fibroblast growth factor 23
(FGF23) also increased in correlationwith phosphate
in the volunteers during canafliglozin treatment
[23
&&
]. FGF23 is a phosphaturic hormone that is
excessively increased during progression of renal
function loss, and it is known for its adverse extra-
renal effects on the heart [26
&
]. FGF23 is secreted by
osteocytes in response to intestinal phosphate
absorption by an unknown mechanism of phos-
phate-sensing, acting toprevent apositivephosphate
balance. Apart from inhibiting phosphate reabsorp-
tion from the proximal tubule by downregulating
NaPi IIa transporters, FGF23 lowers phosphate levels
in two different ways: by the suppression of parathy-
roid hormone (PTH) secretion, reducing phosphate
release from bone, and by inhibiting 1-a-hydroxy-
lase, slowing down the conversion of 25-hydroxy-
cholecalciferol into active vitamin D, or 1.25-
dihydroxycholecalciferol. In turn, 1.25-dihydroxy-
cholecalciferol stimulates phosphate uptake from
the intestine. Indeed, the 1.25-dihydroxycholecalci-
ferol levels of the participants who received canagli-
flozin persistently declined [23
&&
]. PTH, on the other
hand, increased, most likely as a result of the fall in
vitamin D and loss of calcium. The association of
canagliflozin use with a rise in serum phosphate has
been confirmed in clinical studies with diabetic
patients [2,27,28]. Also, in diabetic mice, canagliflo-
zin increased urinary calcium excretion and serum
FGF23 levels [29,30,24].
Similar results were obtained in a posthoc anal-
ysis of the IMPROVE trial in patients with T2DMand
albuminuric kidney disease, in which dapagliflozin
was compared to placebo [31
&&
]. During dapagliflo-
zin treatment, serum phosphate levels increased by
9% and PTH by 16% compared to placebo. FGF23
also significantly increased with 19% [31
&&
]. Other
studies using dapagliflozin confirmed most of these
findings, although an increase in PTH could not be
reproduced in a trial with diabetic patients with
different renal functions [3,9]. In conclusion, SGLT2
inhibitors may increase PTH levels, induced by cal-
ciuria, and increase FGF23, provoked by increased
phosphate reabsorption, concertedly decreasing
active vitamin D.Volume 28  Number 00  Month 2019
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INHIBITORS AND THEIR EFFECTS ON
BONE TURNOVER MARKERS
Bone quality is mainly determined by bone turn-
over, or the rate of bone degradation by osteoclasts
and bone synthesis by osteoblasts. Bone turnover
markers are rapidly responding biomarkers of skele-
tal remodeling with a high interindividual variabil-
ity [27]. Deregulated bone resorption markers are
associated with an increased fracture risk [32]. Some
effects of SGLT2 inhibitors on bone turnover
markers have been documented. In diabetic mice,
the bone resorption marker RatLAPs was increased
compared to control mice [29,30]. Although insulin
therapy attenuated this deviation, canagliflozin fur-
ther increased RatLAPs [29,30]. Reduced levels of
procollagen type 1 N-terminal propeptide (P1NP),
a bone formation marker, in diabetic mice com-
pared to control mice were only seen in one of
two studies by the same group, and there was no
clear effect of canagliflozin on this marker [29,30].
In clinical studies with diabetes type 2 patients,
canagliflozin increased the bone-resorption marker
collagen type 1 b-carboxytelopeptide (CTX) in cor-
relation with weight loss and, in postmenopausal
women, with a decline in osteoclast inhibiting estra-
diol [16,33]. Osteocalcin, a small bone-specific pro-
tein correlated with bone formation, significantly
increased [16,33]. However, there was no evidence
of any effect of dapagliflozin on P1NPor CTX [3,4].
There is no evidence that these alterations in bone
turnovermarkers can be the result of direct binding of
SGLT2 inhibitors to bone tissue. No expression of
SGLT2 was observed in mouse calvarian osteoblasts,
bone marrow macrophages, preosteoclasts or mature
osteoclasts [30]. Another study in rodents reported no
expression of SGLT2 in skeletal tissue or any other
extrarenal tissues [34]. Finally, no binding of intrave-
nously injected4-fluoro-dapagliflozinwasobserved in
bone tissue of rats or mice [35]. Although SGLT2 is
highly specific to the kidney, SGLT1 is also expressed
intheheart, lung,biliary tract,prostate, salivarygland,
trachea, colon, small intestine and in skeletal muscle
tissue [36–40]. To our knowledge, only one study
analyzed SGLT1 expression in bone, which was not
detected [30]. Thus, we consider it unlikely that can-
agliflozin, which has some SGLT1 inhibiting proper-
ties aswell, couldhavedirectoff-targeteffectsonbone.SODIUM GLUCOSE COTRANSPORTER 2
INHIBITORS, BONE MASS DENSITY AND
FRACTURE RISK
The alterations in bone turnover markers associated
with canagliflozin and the rise in PTH and decline in
vitaminD as a result of all SGLT2 inhibitorsmay raise1062-4821 Copyright  2019 The Author(s). Published by Wolters Kluwethequestionwhether such effectwould translate into
an increased fracture risk. Moreover, SGLT2 inhibi-
tor-induced weight loss, which is associated with a
reducedBMDby loweringmechanical forces onbone
tissue, may be an additional factor compromising
bone quality. Especially in women, in whom weight
loss attenuates the activity of aromatases resulting in
lower estradiol levels, the bone density and turnover
can be severely affected [2,33,41].Canagliflozin
The large CANVAS RCT reported an increased inci-
dence of fractures with canagliflozin, which forced
the Food and Drug Administration to release a Drug
Safety Communication and update the drug label [7]
https://www.fda.gov/Drugs/DrugSafety/
ucm461449.htm. In the canagliflozin group, 15.4
fractures were observed per 1000 patient years, com-
pared to 11.9 fractures in the placebo group (HR
1.26; 95% CI 1.04–1.52). Specifically, the incidence
of fractures that occurred in the distal extremities
was increased. Remarkably, when only fractures at
sites known to be at risk for osteoporosis-related
fractures were considered, the difference was no
longer significant.
Another RCT comparing canagliflozin to pla-
cebo in 716 patients with diabetes mellitus type 2
revealed a small but significant decrease in hip BMD
in canagliflozin, which was partially explained by
weight loss [33]. The BMD of the lumbar spine,
femur and arm was not compromised. In a large
cohort study comparing 79964 patients with T2DM
who received canagliflozin with 79964 similar
patients who received a GLP-1 agonist, there was
no significant difference in the occurrence of frac-
tures between both groups [42
&
].
A meta-analysis of nine RCT showed a signifi-
cantly increased fracture risk with canagliflozin
compared to placebo, glimepiride or sitagliptine
[13]. However, the CANVAS trial was by far the
largest study in this analysis and therefore impor-
tantly influenced the overall results. The CANVAS
trial participants were on average older than partic-
ipants from the other trials: 6.7% of CANVAS par-
ticipants were over 75 years, compared to 3.7% of
participants of the other trials [13]. It is therefore
plausible that the a-priori fracture risk was higher in
the CANVAS trial.
In rats, long-term canagliflozin treatment led to
adverse effects on trabecular bone [29].Dapagliflozin
In the DECLARE trial comparing the incidence of
cardiovascular events in dapagliflozin and placebor Health, Inc. www.co-nephrolhypertens.com 5
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Mineral metabolismin 17160 T2DM patients, the fracture risk was simi-
lar in both study arms [5
&
]. A cohort study involving
22618 T2DM patients with a mean follow-up of
12 months showed also no association between
dapagliflozin use and the risk of fractures [43].
Ljunggren et al. [3] and Bolinder et al. [4] measured
BMD in another RCT comparing 182 diabetic
patients whowere all overweight and received either
dapagliflozin or placebo. DEXA scans of the lumbar
spine, femoral neck and hip were performed after
50 weeks of follow-up and no significant differences
in BMD or the incidence of fractures between the
two groups were found [3,4]. Only one smaller RCT
comparing dapaglifozin with 252 participants with
diabetic nephropathy showed a clear relation
between dapagliflozin and fractures: 7.7% of the
patients in the active treatment arm reported a
fracture during 104 weeks of follow-up, compared
to none of the patients who received placebo [9].Empagliflozin
In the EMPAREG-outcomes trial, there were no
indications that empagliflozin-treated patients
had a higher risk of fractures, with an incidence
of 3.7–3.9% depending on the dose compared to
3.9% in the placebo group [6].
Four meta-analyses comparing the use of any
SGLT2 inhibitor with placebo or other control treat-
ments in tens of thousands of patients, including a
Cochrane review in patients with diabetic kidney
disease, did not confirm the relationship between




SGLT2 inhibitors are a new class of antidiabetic
drugs that have demonstrated significant improve-
ments in glycemic parameters and cardiovascular
and renal outcomes in patients with T2DM.
Although a reduced BMD and increased risk of
fractures have been observed in a limited number
of studies with canagliflozin and dapagliflozin, this
has not been confirmed by large meta-analyses and
multiple other trials suggesting that any signals
observed in a few studies are likely to be chance
findings. Mechanistic studies suggest that SGLT2
inhibitors stimulate renal phosphate reabsorption
and calciuria, resulting in increased FGF23 and PTH
and a reduction in active vitamin D. Although
hyperparathyroidism and vitamin D deficiency
could provoke adverse effects on bone, overall such
effects have not been convincingly demonstrated.
Moreover, available data indicate no significant6 www.co-nephrolhypertens.comcorrelation between FGF23 levels and BMD or frac-
ture risk [47].
In the absence of consistent evidence, we advise
to consider the possible adverse bone effects in
vulnerable patients, such as the elderly and patients
with diabetic kidney disease. However, given the
prominent cardio-renal benefits of SGLT2 inhibi-
tors, these drugs should currently not be withheld
based on reports on biomarkers of bone health.
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